Susceptibility and resistance to J3V1 retrovirus-induced murine plasmacytomagenesis in reconstituted severe combined immunodeficient mice
- PMID: 7685514
Susceptibility and resistance to J3V1 retrovirus-induced murine plasmacytomagenesis in reconstituted severe combined immunodeficient mice
Abstract
To date much is known about the genetics of susceptibility and resistance to plasmacytoma induction in mice, however little is known about the cellular aspects of these phenotypes. The complexity of plasmacytomagenesis allows for susceptibility and resistance to reflect differences in B cells, T cells, accessory cells and/or stromal elements contributing to the disease process. Alternatively, these phenotypes may result from differential abilities to affect events critical to plasmacytomagenesis, such as myc deregulation. To address these possibilities, the v-myc-raf-containing retrovirus, J3V1, was used to induce plasmacytomas (PCTs) in severe combined immunodeficient (SCID) mice reconstituted with susceptible (Balb/c) and/or resistant (DBA/2) cells. The results demonstrate that Balb/c bone marrow (BM)-reconstituted SCID mice yielded PCTs of donor origin, while DBA/2 BM-reconstituted mice did not. Mice reconstituted with both DBA/2 BM and Balb/c peripheral lymphocytes, as well as those reconstituted with Balb/c peripheral lymphocytes alone, also yielded only Balb/c PCTs. These results indicate that: (1) a microenvironment supportive of plasmacytomagenesis is insufficient to allow PCT development among resistant cells; (2) DBA/2 BM-derived cells do not suppress plasmacytomagenesis by target cell elimination or microenvironment destruction; (3) resistance is not solely attributable to the inability of DBA/2 B cells to deregulate myc; and (4) potential PCT targets reside in a number of lymphoid tissues. Taken together, these results demonstrate that a major aspect of resistance/susceptibility to plasmacytomagenesis is dictated by the genotype of the target B cell.
Similar articles
-
Nonrandom chromosomal change (trisomy 11) in murine plasmacytomas induced by an ABL-MYC retrovirus.Cancer Res. 1995 Mar 1;55(5):1181-8. Cancer Res. 1995. PMID: 7867005
-
Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice.Cancer Res. 1994 Feb 15;54(4):969-75. Cancer Res. 1994. PMID: 8313388
-
Association of elevated mutagenesis in the spleen with genetic susceptibility to induced plasmacytoma development in mice.Cancer Res. 1998 Apr 15;58(8):1616-9. Cancer Res. 1998. PMID: 9563470
-
Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations.Carcinogenesis. 1992 Oct;13(10):1681-97. doi: 10.1093/carcin/13.10.1681. Carcinogenesis. 1992. PMID: 1423827 Review.
-
Indomethacin inhibition of pristane plasmacytomagenesis in genetically susceptible inbred mice.Adv Exp Med Biol. 1999;469:151-6. doi: 10.1007/978-1-4615-4793-8_23. Adv Exp Med Biol. 1999. PMID: 10667324 Review. No abstract available.
Cited by
-
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.Cancer Immunol Immunother. 2007 Mar;56(3):343-57. doi: 10.1007/s00262-006-0196-9. Epub 2006 Jul 11. Cancer Immunol Immunother. 2007. PMID: 16832681 Free PMC article.
-
T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):649-53. doi: 10.1073/pnas.92.3.649. Proc Natl Acad Sci U S A. 1995. PMID: 7846031 Free PMC article.
-
Assessment of all-trans retinoic acid (ATRA) efficacy as a single agent in primary lymphoid neoplasia.Med Oncol. 1999 Jul;16(2):119-28. doi: 10.1007/BF02785845. Med Oncol. 1999. PMID: 10456660
-
Interleukin 6 is essential for in vivo development of B lineage neoplasms.J Exp Med. 1995 Jul 1;182(1):243-8. doi: 10.1084/jem.182.1.243. J Exp Med. 1995. PMID: 7790819 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous